Albany, NY -- (SBWIRE) -- 10/07/2019 -- Acute Lymphoblastic Leukemia Market Insights, Epidemiology and Market Forecast-2028

1. The estimated worldwide annual adult acute lymphoblastic leukaemia incidence is about 1 in 100,000.
2. The acute lymphoblastic leukaemia incidence follows a bimodal distribution, with the first peak occurring in childhood and a second peak occurring around the age of 50.
3. The number of new cases of acute lymphoblastic leukemia was 1.7 per 100,000 per year based on 2012–2016 cases.
4. There are estimated 5930 new cases of acute lymphoblastic leukemia in which 3280 are males and 2650 are females.

(Albany, US) DelveInsight launched a new report on acute lymphoblastic leukemia Market Insights, Epidemiology and Market Forecast-2028

Key benefits

1. Acute lymphoblastic leukemia market report covers a descriptive overview and comprehensive insight of the Acute lymphoblastic leukemia epidemiology and Acute lymphoblastic leukemia market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Acute lymphoblastic leukemia market report provides insights on the current and emerging therapies.
3. Acute lymphoblastic leukemia market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Acute lymphoblastic leukemia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Acute lymphoblastic leukemia market.

Request for sample pages

"About 3000 children in the United States and 5000 children in Europe are diagnosed with acute lymphoblastic leukemia per year and the peak incidence occurs between 2 and 5 years of age."

Acute lymphoblastic leukemia treatment typically spans 2–2.5 years and Chemotherapy (chemo) is the mainstay treatment for nearly all cases. Chemotherapy consists of induction, consolidation and long-term maintenance, with CNS prophylaxis given at intervals throughout therapy.

Some types of high-risk Acute lymphoblastic leukemia such as T-cell Acute lymphoblastic leukemia or Acute lymphoblastic leukemia infants or in adults are usually treated with higher doses of drugs during induction, consolidation and maintenance therapy. Stem cell Therapy has been considered the standard-of-care and the best chance for a durable response with relapsed/refractory disease.

The current status of the development of novel antileukemic agents have changed, as few companies have recently shifted their focus toward this indication, yet others are expected to create a significant influence on Acute lymphoblastic leukemia market size of during the forecast period. The extensive research in the field of ALL is ongoing which will help to understand the mechanisms that control leukemic cells, facilitating the design of new drugs that specifically interfere with leukemic pathways and overcome chemo-resistance induced by common treatment regimens.

The launch of the emerging therapies is expected to significantly impact Acute lymphoblastic leukemia treatment scenario in the upcoming years:-

Drugs covered
1. AUTO3
2. KTE-X19
3. Isatuximab
4. TBI-1501
5. BinD 19
6. K0706
And many others

The key players in Acute lymphoblastic leukemia market are:
1. Allogene Therapeutics
2. Autolus Therapeutics
3. Kite Pharma
4. Sanofi
5. Sun Pharma Advanced Research
6. Takara Bio
And many others

Table of contents

1. Report Introduction
2. Acute Lymphoblastic Leukemia Market Overview at a Glance
3. Acute Lymphoblastic Leukemia Disease Background and Overview
4. Acute Lymphoblastic Leukemia Epidemiology and Patient Population
4.1. Assumptions and Caveats
4.2. 7MM Incident cases of Acute Lymphoblastic Leukemia (2017–2028)
4.3. Age-Specific cases of Acute Lymphoblastic Leukemia (2017–2028)
4.4. Gender-Specific cases of Acute Lymphoblastic Leukemia (2017–2028)
4.5. Diagnosed and Treatable cases of Acute Lymphoblastic Leukemia (2017–2028)
4.6. Acute Lymphoblastic Leukemia: Country- Wise Epidemiology
4.7. United States
4.8. EU-5
4.9. Assumptions and Rationale
4.10. Germany
4.11. France
4.12. Italy
4.13. Spain
4.14. United Kingdom
4.15. Japan
5. Acute Lymphoblastic Leukemia Treatments & Medical Practices
6. Acute Lymphoblastic Leukemia Marketed Therapies
6.1. Kymriah: Novartis
6.2. Besponsa: Pfizer
6.3. Blinatumomab: Amgen
7. Acute Lymphoblastic Leukemia Emerging Therapies
8. Key Cross Competition
8.1. AUTO3: Autolus Therapeutics
8.2. Isatuximab: Sanofi
8.3. KTE-X19: Kite Pharma
8.4. TBI-1501:Takara Bio
9. Acute Lymphoblastic Leukemia Market Size
10. 7MM Acute Lymphoblastic Leukemia: Country-Wise Market Analysis
11. United States Market Size
12. Germany Market Size
13. France Market Size
14. United Kingdom Market Size
15. Spain Market Size
16. Italy Market Size
17. Japan Market Size
18. Acute Lymphoblastic Leukemia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight